Combined effects of NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism and smoking on bladder cancer risk: Two meta-analyses
原文： 2017 年 发布于
Urol Oncol
浏览量：169次
作者：
Wang X. C.
Wang J.
Tao H. H.
Zhang C.
Xu L. F.
作者单位：
Department of Urology, Medical University of Vienna, Vienna, Austria
Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. Department of Urology, Medical University of Vienna, Vienna, Austria
Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. Department of Epidemiology, Harvard T.H Chan School of Public Health, Boston, MA, USA
Channing Division of Network Medicine, Department of Medicine, Harvard Medical School, Boston, MA, USA
Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria. Department of Urology, Medical University of Vienna, Vienna, Austria
Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. Department of Urology, Medical University of Vienna, Vienna, Austria
Department of Urology, Jikei University School of Medicine, Tokyo, Japan. Department of Urology, Medical University of Vienna, Vienna, Austria. Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Department of Urology, University of Montreal, Montreal, Quebec, Canada. Department of Urology, Medical University of Vienna, Vienna, Austria
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. Electronic address: sfshariat@gmail.com.
归属分类：
膀胱肿瘤病因/危险因素证据
DOI：
10.1002/cam4.3513
People with type 2 diabetes are at increased risk of bladder cancer. Pioglitazone is said to increase it further, although published evidence is mixed. We conducted a meta-analysis to determine if any link between the use of pioglitazone and an increased risk of bladder cancer can be found. A comprehensive literature search was conducted through electronic databases as well as registries for data of clinical trials to identify studies that investigate the effect of pioglitazone on bladder cancer in diabetic patients. We used the risk ratio (RR) and the hazard ratio (HR) provided by the studies to illustrate the risk of occurrence of bladder cancer in the experimental group compared to that in the control group. Fourteen studies using RR and 12 studies using HR were included in the analysis. The overall RR was 1.13 with 95% CI (0.96-1.33) with low heterogeneity among the studies using RR, suggesting that no connection exists between use of pioglitazone and the risk of bladder malignancy. The summary HR was 1.07 (0.96-1.18) allowing us to affirm that there is no link between long-term use of pioglitazone and bladder cancer. Our results support the hypothesis of no difference in the incidence of bladder cancer among the pioglitazone group and the nonuser group. Our conclusion is that the explanation of hypothetically increased risk of bladder malignancy should be attributed to other factors. FUNDING: Tchaikapharma High Quality Medicines Inc.